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Abstract
Background: Buruli Ulcer (BU) is a neglected, necrotizing skin disease caused by Mycobacterium ulcerans. Currently, there is
no vaccine against M. ulcerans infection. Although the World Health Organization recommends a combination of rifampicin
and streptomycin for the treatment of BU, clinical management of advanced stages is still based on the surgical resection of
infected skin. The use of bacteriophages for the control of bacterial infections has been considered as an alternative or to be
used in association with antibiotherapy. Additionally, the mycobacteriophage D29 has previously been shown to display
lytic activity against M. ulcerans isolates.
Methodology/Principal findings: We used the mouse footpad model of M. ulcerans infection to evaluate the therapeutic
efficacy of treatment with mycobacteriophage D29. Analyses of macroscopic lesions, bacterial burdens, histology and
cytokine production were performed in both M. ulcerans-infected footpads and draining lymph nodes (DLN). We have
demonstrated that a single subcutaneous injection of the mycobacteriophage D29, administered 33 days after bacterial
challenge, was sufficient to decrease pathology and to prevent ulceration. This protection resulted in a significant reduction
of M. ulcerans numbers accompanied by an increase of cytokine levels (including IFN-c), both in footpads and DLN.
Additionally, mycobacteriophage D29 treatment induced a cellular infiltrate of a lymphocytic/macrophagic profile.
Conclusions/Significance: Our observations demonstrate the potential of phage therapy against M. ulcerans infection,
paving the way for future studies aiming at the development of novel phage-related therapeutic approaches against BU.
Citation: Trigo G, Martins TG, Fraga AG, Longatto-Filho A, Castro AG, et al. (2013) Phage Therapy Is Effective against Infection by Mycobacterium ulcerans in a
Murine Footpad Model. PLoS Negl Trop Dis 7(4): e2183. doi:10.1371/journal.pntd.0002183
Editor: Christian Johnson, Fondation raoul Follereau, France
Received December 19, 2012; Accepted March 18, 2013; Published April 25, 2013
Copyright:  2013 Trigo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a grant from the Health Services of Fundac¸a˜o Calouste Gulbenkian, and the Portuguese Science and Technology
Foundation (FCT) fellowships SFRH/BPD/64032/2009, SFRH/BD/41598/2007, and SFRH/BPD/68547/2010 to GT, TGM, and AGF, respectively. The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jpedrosa@ecsaude.uminho.pt
Introduction
Buruli Ulcer (BU), caused by Mycobacterium ulcerans, is an
emerging, devastating skin disease reported in more than 30
countries, mainly in West Africa [1,2]. BU is characterized by
different clinical forms, including nonulcerative subcutaneous
nodules, papules, edema, and plaques that can progress to necrotic
ulcerative forms. The pathogenesis of BU is associated with
mycolactone, a lipidic exotoxin presenting cytotoxic and immu-
nosuppressive properties [3–7]. Prevention is difficult as little is
known about disease transmission, although it has been shown that
M. ulcerans is an environmental pathogen [8–10], and no vaccine is
available.
Since 2004, the World Health Organization (WHO) recom-
mends the treatment of BU with a combination of rifampicin and
streptomycin (RS) [11]. Nevertheless, this treatment presents several
limitations: (i) it does not resolve extensive lesions (as a result,
surgery is the only alternative) [12]; (ii) the long period of
administration of streptomycin by muscular injection demands
skilled personnel; (iii) it is associated with adverse side effects [13,14]
leading to poor compliance; and (iv) importantly, it may lead to the
occurrence of paradoxical reactions associated with the worsening
of the lesion and/or the appearance of new lesions [14–18].
Bacteriophages (phages) have been proposed to treat human
bacterial infections since their discovery in the early 20th century
[19]. Several well controlled studies in both animal models and
human infections have successfully applied phage therapy to
several types of bacterial infections, demonstrating its potential as
an antibacterial therapy in vivo [20–30] Additionally, in the UK,
the first phase II clinical trial performed under European
regulations on phage treatment of chronic otitis has open the
door for novel phage-based human applications [31].
Phage therapy presents several potential advantages for the
treatment of BU patients, namely phages present lytic activity
against extracellular bacteria which predominate in advanced
lesions; phages may be used for the treatment of ulcerative lesions
where the necrotic infection site would be accessible; and phages
may be administered topically [28].
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In the present study, following the screening of the lytic activity
of several mycobacteriophages, the therapeutic effect of the
selected mycobacteriophage D29 was evaluated against M. ulcerans
in the mouse footpad model of infection. The progression of
macroscopic/microscopic pathology and bacterial load, as well as
the cytokine profile, in both the footpad and the draining lymph
node (DLN), were evaluated after mycobacteriophage D29
administration.
Materials and Methods
In vitro mycobacteriophage activity against M. ulcerans
Mycobacteriophages, kindly provided by Dr. Graham F. Hatfull
from the Pittsburgh Bacteriophage Institute and Department of
Biological Sciences, University of Pitsburgh, were screened against
M. ulcerans isolates. In order to select mycobacteriophages active
against M. ulcerans strains, we first selected representative isolates of
M. ulcerans from endemic BU areas, based on their genetic and
phenotypic characteristics, including the type of mycolactone
produced [3,32,33] and their virulence in mice [7,34] (see Table 1).
The strains were obtained from the collection of the Institute of
Tropical Medicine (ITM), Antwerp, Belgium.
This host-range determination was done by adapting a spot-test
technique described elsewhere [35,36]. Briefly, M. ulcerans was
grown to an OD600 of 1.0 and clumps were dispersed by passing
the bacterial suspension several times through a 25-gauge needle.
The suspension was plated on Middlebrook 7H9 agar medium
(Becton, Dickinson and Company). For each mycobacteriophage,
serial dilutions were prepared in phage buffer (MPB) (10 mM Tris,
pH 7.5, 1 mM MgSO4, 70 mM NaCl) and were plated onto the
M. ulcerans lawn and the spots were allowed to dry completely.
Plates were incubated at 32uC for approximately 6–8 weeks.
Animals
A total of 120 (per experience) eight-week-old female BALB/c
mice were obtained from Charles River (Barcelona, Spain) and
were housed under specific-pathogen-free conditions with food
and water ad libitum.
Footpad mouse model of M. ulcerans infection
M. ulcerans 1615 is a mycolactone A/B producing strain isolated
in Malaysia from an ulcerative case [7]. The isolate was grown on
Middlebrook 7H9 agar medium at 32uC for approximately 6–8
weeks. For the preparation of inoculum, M. ulcerans was recovered,
diluted in phosphate-buffered saline (PBS) and vortexed using glass
beads. The number of acid-fast bacilli (AFB) in inocula were
determined as described previously using Ziehl-Neelsen (ZN)
staining [37]. Mice were infected in the left hind footpad with
0.03 ml of M. ulcerans suspension containing 5.5 log10 AFB.
Treatment of M. ulcerans-infected mice with
mycobacteriophage D29
D29 particles were propagated in Mycobacterium smegmatis mc2155
(ATCC), as described elsewhere [36]. In brief, approximately 105
phage particles and 250 ml of M. smegmatis mc2155 (ATCC) (OD600
of 1.0) were plated on Middlebrook 7H9 overlays (0.6% agar) and
incubated at 37uC overnight. Phage particles were extracted with
3 ml of MPB and harvested filtering through a 0.2 mm pore-size
filter. Phages were concentrated through polyethylene glycol (PEG)
precipitation and purified using a CsCl equilibrium density gradient
centrifugation. Phage titers (PFU/ml) were determined by serial
dilution and plaque assays by the soft overlay technique with some
modifications [35]. Briefly, phage dilutions were spotted onto
Middlebrook 7H9 overlays (0.6% agar) with M. smegmatis mc2155
(ATCC) and incubated at 37uC overnight.
The treatment was initiated at day 33 post-infection, when the
footpad of mice were swollen to 3.0 mm, and was performed by
subcutaneous injection in the infected footpad with a single dose of
mycobacteriophage D29 containing 8 log10 PFU. MPB was given
to control (non-treated) mice.
Assessment of footpad swelling
Footpad swelling was monitored throughout the experiment, as
an index of lesion development, by using a caliper to measure the
diameter of the frontal area of the footpad. For ethical reasons, the
non-treated mice were sacrificed after the emergence of ulceration
at day 68 post-infection, and no further parameters were evaluated
for this group.
Bacterial and phage growth
M. ulcerans growth and phage proliferation were evaluated in
footpad tissues and in the DLN. Briefly, footpad tissue specimens
Table 1. Characteristics of M. ulcerans isolates used.
M. ulcerans Origin
Geographical
origin
Type of
Mycolactone
98-912 Ulcer China D
97-1116 Plaque Benin A/B
1615 Ulcer Malaysia A/B
94-1331 nd Papua New Guinea A/B
94-1327 Ulcer Australia C
5114 Ulcer Mexico -
00-1441 Ulcer Benin A/B
94-1324 Aquatic insect Australia C
03-216 Ulcer Benin A/B
nd, not determined; -, Mycolactone negative.
doi:10.1371/journal.pntd.0002183.t001
Author Summary
Buruli Ulcer (BU), caused by Mycobacterium ulcerans, is a
necrotizing disease of the skin, subcutaneous tissue and
bone. Standard treatment of BU patients consists of a
combination of the antibiotics rifampicin and streptomycin
for 8 weeks. However, in advanced stages of the disease,
surgical resection of the destroyed skin is still required. The
use of bacterial viruses (bacteriophages) for the control of
bacterial infections has been considered as an alternative
or a supplement to antibiotic chemotherapy. By using a
mouse model of M. ulcerans footpad infection, we show
that mice treated with a single subcutaneous injection of
the mycobacteriophage D29 present decreased footpad
pathology associated with a reduction of the bacterial
burden. In addition, D29 treatment induced increased
levels of IFN-c and TNF in M. ulcerans-infected footpads,
correlating with a predominance of a mononuclear
infiltrate. These findings suggest the potential use of
phage therapy in BU, as a novel therapeutic approach
against this disease, particularly in advanced stages where
bacteria are found primarily in an extracellular location in
the subcutaneous tissue, and thus immediately accessible
by lytic phages.
Phage Therapy: M. ulcerans Experimental Infection
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were minced, resuspended in PBS (Sigma) and vortexed with glass
beads to obtain homogenized suspensions. DLN were homoge-
nized, the cell numbers were counted and then suspensions were
lysed with saponin 0.1%. Serial dilutions of the footpad and DLN
homogenates were plated on Middlebrook 7H9 agar medium. M.
ulcerans numbers were counted after 6 to 8 weeks of incubation at
32uC and expressed as colony forming units (CFU/ml). Homog-
enized samples were also centrifuged for 10 min at 5000 rpm,
supernatant was used for phage determination by the soft overlay
technique [35] and expressed as plaque forming units (PFU/ml).
Phage dissemination was also investigated by detecting phages in
the spleen and sera of mice.
Detection of cytokines
The levels of the cytokines tumor necrosis factor (TNF),
interleukin (IL)-6, gamma interferon (IFN-c) and IL-10 in the
supernatant of homogenized suspensions from DLN and footpad
tissues of control-infected and mycobacteriophage D29 treated
mice were quantified by using a Quantikine Murine ELISA kit
(eBioscience Inc), according to the manufacturer’s instructions.
Histological studies
Mouse footpads and DLN were harvested, fixed in 10%
phosphate-buffered formalin and embedded in paraffin. Light
microscopy studies were performed on tissue sections stained with
hematoxylin and eosin (HE) or Ziehl-Neelsen (ZN). Images were
obtained with an Olympus BX61 microscope.
Statistical analysis
Differences between the means of experimental groups were
analyzed with the two-tailed Student t test. Differences with a P
value of #0.05 were considered significant.
Ethics statement
This study was approved by the Portuguese national authority
for animal experimentation Direc¸a˜o Geral de Veterina´ria (ID:
DGV 594 from 1st June 2010). Animals were kept and handled in
accordance with the guidelines for the care and handling of
laboratory animals in the Directive 2010/63/EU of the European
Parliament and of the Council.
Results
Mycobacteriophage D29 shows a broad lytic activity
against M. ulcerans isolates in vitro
We first tested the lytic activity of different mycobacterio-
phages against several M. ulcerans isolates. The results for the
plaque formation on the tested M. ulcerans strains are given in
Table 2. We observed that some phages were more strain-
specific, such as the phages Adjutor, Kostya and Brujita, and
others presented a more narrow lytic host range spectrum (L5,
Chah and Phaedrus). A cluster of three phages, namely D29,
Bxz2 and Tweety, displayed the broadest lytic host range
spectrum and highest lytic activity against representative strains
of M. ulcerans. In line with a previous report [36], D29 phage
showed the broadest lytic host range spectrum amongst the
tested mycobacteriophages, affecting M. ulcerans isolates with
genetic heterogeneity, variable phenotypic characteristics and
from different geographic origins (Table 1). Based on these
results, we selected mycobacteriophage D29 for in vivo thera-
peutic studies against infection with M. ulcerans 1615, a well
characterized and stable strain that presents a mycolactone
profile identical to that of African strains [32].
Treatment with mycobacteriophage D29 prevents
ulceration caused by M. ulcerans and decreases the
bacterial load in both the footpad and the DLN
To investigate the efficacy of mycobacteriophage D29 treatment
for the control of M. ulcerans, we used a footpad mouse model of
infection [34,38,39]. Mice were subcutaneously infected in
footpads with 5.5 log10 AFB of M. ulcerans strain 1615. At day
33 post-infection, when footpad swelling had reached 3.0 mm
(Figure 1A), mice were subcutaneously injected in the footpad with
a single dose of mycobacteriophage D29 (8 log10 PFU) or with the
vehicle MPB as a control.
In both control-infected and mycobacteriophage D29 treated
mice we observed an initial footpad swelling (Figure 1A). However,
at day 68 post-infection, footpads of non-treated mice started
showing signs of ulceration, while in mycobacteriophage D29
treated mice the progression of swelling halted after day 91 post-
infection (day 58 post-treatment) (Figure 1A). Furthermore, in
mycobacteriophage D29 treated mice, we observed a progressive
reduction of footpad swelling, until initial treatment values,
recorded by day 150 post-infection. Moreover, signs of ulceration
were continuously absent during the period of experimental
infection (Figure 1A). The administration of mycobacteriophage
D29 or vehicle MPB alone did not induce significant swelling of
the footpad (data not shown).
Regarding M. ulcerans growth in infected footpads of non-treated
mice, we observed a significant bacterial proliferation over the
course of experimental infection (P,0.01) (Figure 1B). On the
other hand, in footpads of mycobacteriophage D29 treated mice,
we observed a significant reduction in CFU counts (P,0.001) at
day 68 post-infection (day 35 post-treatment), following the
administration of a single dose of mycobacteriophage D29 on
day 33 post-infection (Figure 1B).
As previously described [38–40], we found that M. ulcerans
disseminates to the DLN after footpad infection (Figure 1C ),
probably due to continuous lymphatic dissemination of bacteria
either freely or shuttled within phagocytes. Here we show a
significant reduction in CFU counts (P,0.05) in the DLN of
mycobacteriophage D29 treated mice, as compared with non-
treated counterparts, at day 68 post-infection (day 35 post-
treatment) (Figure 1C), correlating with the reduction of M. ulcerans
numbers in the footpads.
Mycobacteriophage D29 disseminates from footpad to
the DLN
It is well known that bacteriophages can disseminate from the
administration site and reach several organs such as lymph nodes,
spleen and liver, which are the primary sites involved in phage
clearance [41,42]. In order to investigate the possible dissemina-
tion of mycobacteriophage D29, we determined phage titres in the
footpad, DLN, spleen and blood after its inoculation in M. ulcerans
infected footpads.
As shown in Figure 2, mycobacteriophage D29 numbers
significantly decreased (P,0.001) in infected footpads from 2 to
24 h post-treatment and no phages could be detected after this
time point (Figure 2). Phage numbers were also detected in the
DLN, as early as 2 h after the administration in infected footpads,
time point at which maximum phage counts were obtained
(Figure 2). After 24 h, we observed a significant decrease
(P,0.001) in phage titers in the DLN, but phages were still
present until day 15 post-treatment (Figure 2). No phages could be
detected in the DLN by the end of the experimental period of
infection (day 35 post-treatment) (Figure 2).
Phage Therapy: M. ulcerans Experimental Infection
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Table 2. Sensitivity of phages to M. ulcerans isolates.
Phage
M. ulcerans D29 Bxz2 L5 Tweety Chah Adjutor Kostya Phaedrus Brujita
98-912 P - - - P - P - -
97-1116 P P P - - - - - -
1615 P - - - - - - - -
94-1331 P - - - - - - - -
94-1327 - - - P - P - - -
5114 P P - P - - - P -
00-1441 P P - P P - - - P
94-1324 P P P P - - - P -
03-216 P - - - - - - - -
P-plaque formation.
doi:10.1371/journal.pntd.0002183.t002
Figure 1. Lesion progression andM. ulcerans proliferation in the footpads and DLN of infected mice. Mice were infected subcutaneously
in the left footpad with 5.5 log10 AFB of M. ulcerans strain 1615. After the emergence of macroscopic lesion (33 days post infection; footpad swelling
of 3.0 mm) mice were subjected to treatment with a single dose of subcutaneous injection of mycobacteriophage D29 (dashed line). Lesion
progression was assessed by measurement of footpad swelling (panel A) (n = 15). Bacterial proliferation was assessed by colony forming units in
footpads (panel B) and in DLN (panel C) (n = 5). {, mice were sacrificed for ethical reasons after the emergence of ulceration of non-treated mice (68
days post infection). Results are from one representative experiment of two independent experiments. Data points and bars represent the mean 6
SD (n = 5). Significant differences between treated and non-treated mice were performed using Student’s t test (*, p#0.05, **, p#0.01, ***, p#0.001).
doi:10.1371/journal.pntd.0002183.g001
Phage Therapy: M. ulcerans Experimental Infection
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D29 phages were also detected in the spleen (2.2 log1060.25)
and in the serum (2.3 log1060.17) of mycobacteriophage D29
treated mice as early as 2 h post-treatment but were no longer
detectable until the end of the experimental period.
Increased levels of TNF, IFN-c, and IL-10, but not IL-6,
were induced in the footpad and DLN following
treatment with mycobacteriophage D29
To characterize the profile of the immune response in M.
ulcerans-infected tissues and to determine how phage treatment
influences the host response, we carried out a comparative analysis
of cytokine kinetics in DLN and footpads.
Regarding the production of the pro-inflammatory cytokine
tumor necrosis factor (TNF) in the DLN, at the emergence of
ulceration, protein levels were no longer detectable in non-treated
mice. In comparison, in mycobacteriophage D29 treated mice,
significant levels of TNF were detectable at day 68 post-infection
(day 35 post-treatment) (Figure 3A). Treatment with mycobacter-
iophage D29 also resulted in a significant increase of TNF levels in
footpads of M. ulcerans infected mice (P,0.01) at day 35 post-
treatment (day 68 post-infection), as compared with non-treated
mice (Figure 3B).
Protein levels of IL-6 were detected in DLN and footpads of M.
ulcerans infected mice at day 33 post-infection (Figure 3C and D).
At day 68 post-infection (35 days post-treatment), higher levels of
IL-6 were detected in footpads of infected non-treated mice
(P,0.01), as compared with mycobacteriophage D29 treated mice
(P,0.05) (Figure 3D).
As shown in Figure 3E and F, treatment with mycobacterioph-
age D29 resulted in a significant increase in the levels of IFN-c in
both the DLN and footpads (P,0.05), at day 35 post-treatment
(day 68 post-infection) as compared with non-treated mice
(Figure 3E and F).
The production of the anti-inflammatory cytokine IL-10 was
also increased in both DLN and footpads of mycobacteriophage
D29 treated mice (Figure 3G and H), as compared to non-treated
mice at day 68 post-infection.
D29 treatment is associated with the development and
maintenance of a local mononuclear inflammatory
response to M. ulcerans
Histopathological analysis showed that at day 68 post-infection
necrotic lesions (Figure 4A) were well established in the footpad
tissue, as previously described in M. ulcerans progressing lesions
from both humans and mice [34,43]. Necrotic tissue was
surrounded by an inflammatory infiltrate composed mainly by
macrophages (Figure 4B). These necrotic areas, as expected,
contained clumps of extracellular bacilli correlating with the
emergence of footpad ulceration (Figure 4C). At the same time
point (day 35 after treatment) in mycobacteriophage D29 treated
mice, we observed an abundant cellular infiltration (Figure 4D)
with a predominance of lymphocytes and macrophages
(Figure 4E). We also observed bacilli, but they mainly co-localized
with cells (Figure 4F and G). In addition, the maintenance of these
inflammatory infiltrates (Figure 4H) mainly composed by mono-
nuclear cells (Figure 4I), was observed 5 months after the end of
mycobacteriophage D29 treatment. Although some bacilli were
observed in the remaining necrotic areas (Figure 4J), as well at the
periphery (Figure 4K), they were poorly stained by ZN.
To determine the effect of D29 phage inoculation, a group of
mice was injected only with the phage. The histological analysis
shows no significant alterations in subcutaneous tissues of non-
infected mice inoculated with mycobacteriophage D29, at least
until the end of the experimental period (day 150 after treatment)
(data not shown).
D29 treatment prevents DLN destruction
Analysis of histopathology at day 68 post-infection showed that,
in non-treated animals, the structure of the DLN was damaged,
with absence of organized germinal centers leading to the
destruction of the lymphoid tissue (Figure 5A), as recently reported
in experimental M. ulcerans infection [38]. On the other hand, in
D29 phage-treated mice the structure of the DLN was maintained
with mild alterations (Figure 5B).
Previous studies from our laboratory showed that the initial
increase of cell numbers in the DLN, upon footpad infection by M.
ulcerans, is followed by a rapid decrease, correlating with the
destruction of lymphoid tissue [38,39].
Confirming previous results, here we observed a significant peak
in the total cells (P,0.05) at day 33 post-infection, followed by a
sharp decrease observed at day 68 post-infection (Figure 5C). We
now show that mycobacteriophage D29 treatment induced a
significant increase in the total number of cells in the DLN
(P,0.05) at day 68 post-infection (day 35 after treatment).
Discussion
The RS regimen for BU, recommended by the WHO [11], is
effective for small lesions but presents several limitations and
adverse side effects. Additionally, the RS regimen presents a
variation in efficacy for advanced ulcerative stages of the disease,
for which the adjunction of surgical resection of the infected skin
followed by skin graft is often required [44].
The use of bacteriophages in targeting bacteria, even antibiotic
resistant ones, has been regarded as an alternative method to
control bacterial infections in both animals and humans
[20–31,45].
In fact, some studies have applied phage therapy to prevent and
treat bacterial human diseases, such as the use of a novel,
Figure 2. Mycobacteriophage D29 dissemination in footpads
and DLN of mycobacteriophage D29-treated mice. Mice were
infected subcutaneously in the left footpad with 5.5 log10 AFB of M.
ulcerans strain 1615. After the emergence of macroscopic lesion (33
days post infection; footpad swelling of 3.0 mm) mice were subjected
to treatment with a single dose of subcutaneous injection of
mycobacteriophage D29. Phage titres were assessed by plaque forming
units. n.d., not detected. Results are from one representative
experiment of two independent experiments. The bars represent the
mean 6 SD (n = 5). Significant differences were performed using
Student’s t test (**, p#0.01, ***, p#0.001).
doi:10.1371/journal.pntd.0002183.g002
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Figure 3. Cytokine profile in DLN and footpads of non-treated mice or mycobacteriophage D29-treated mice. Mice were infected
subcutaneously in the left footpad with 5.5 log10 AFB of M. ulcerans strain 1615. After the emergence of macroscopic lesion (33 days post infection;
footpad swelling of 3.0 mm) mice were subjected to treatment with a single dose of subcutaneous injection of mycobacteriophage D29. Levels of the
TNF (panel A and B), IL- 6 (panel C and D), IFN-c (panel E and F) and IL-10 (panel G and H) in DLN (panel A, C, E and G) and footpads (panel B, D, F and
H) of mice were quantified by ELISA assay. n.d., not detected. Results are from one representative experiment of two independent experiments. Bars
Phage Therapy: M. ulcerans Experimental Infection
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biodegradable preparation capable of releasing bacteriophages
and ciprofloxacin (PhagoBiodermTM), successfully used for the
treatment of patients with severe radiation burns infected with
multidrug-resistant Staphylococcus aureus [28]. In addition, early
studies suggest that phage therapy may have potential for the
treatment of mycobacterial diseases. Indeed, a reduction of lesions
in the spleen, lungs and livers has been reported in experimentally
infected guinea pigs with disseminated tuberculosis following
therapy with phage DS-6A [46].
Previous reports suggest the potential use of mycobacteriophage
D29 for the detection of M. ulcerans or for the assessment of drug
resistance among mycobacterial isolates [36,46]. In this study, we
have demonstrated for the first time the potential of phage therapy
against M. ulcerans infection. Indeed, we have shown in the mouse
footpad model that a single subcutaneous injection of the lytic
mycobacteriophage D29 can effectively decrease the proliferation
of the mycolactone-producing M. ulcerans 1615. Importantly,
mycobacteriophage D29 also showed lytic activity against several
other M. ulcerans isolates in vitro, indicating that its activity in vivo
may not be limited to M. ulcerans 1615.
As described, intravenous injection of phages enables a fast and
directed introduction of phages in blood circulation and their
spread through the organism [42]. Additionally, it has been
described in mice that phages can also reach several organs,
including lungs, kidney, spleen, liver and brain within 24 h after
administration by other routes, including oral and traqueal routes
[42]. Based on these observations, we studied the dissemination of
mycobacteriophage D29 after subcutaneous injection in infected
footpads. We show that mycobacteriophage D29 could only be
detected in the blood and spleen of mice at 2 h post-injection,
while in the footpad phages were detected until 24 h after
injection. On the other hand, phages could be found in the DLN
for longer periods of time, remaining viable for at least 15 days.
The rapid elimination of phages from the circulation and their
retention in the DLN as observed in our study, may be responsible
for reducing the number of phages to a level that prevents
complete bacterial clearance in infected footpads.
One possible approach to solve this rapid phage clearance,
observed in both the footpads and the blood, may be through the
administration of a long-lived circulating phage strain, as
described in the case of other infection models [22,47,48].
Although using a high phage dose could also result in a decrease
of phage clearance, studies have shown that this approach may
result in bacterial death without phage replication [47,49,50] and
also lead to a drop in the phage titer, effectively diminishing the
dose of active phages.
Additionally, phage replication only occurs when the bacterial
density is above a certain threshold [51]. This threshold is reached
in the course of systemic infections [22,48,52], but may be
compromised in the case of necrotic lesions, such as those induced
by M. ulcerans infections. As described in phage treatment of a local
S. aureus infection, even with multiple subcutaneous doses of
109 PFU/mouse, phages significantly reduced but did not
eliminate the bacterial load in abscesses induced by bacteria [22].
A possible concern about phage therapy is the emergence of
phage-resistant bacteria [22,24,48,53]. Although in this study we
do not provide data related to the emergence of M. ulcerans phage-
resistance, it has been described, in experimental models of other
bacterial diseases, namely with Pseudomonas aeruginosa, Escherichia coli
and S. aureus, that phage resistance is a rare event [22,24,48], even
represent the mean 6 SD (n = 5). Significant differences between treated and non-treated mice were performed using Student’s t test (*, p#0.05,
**, p#0.01, ***, p#0.001).
doi:10.1371/journal.pntd.0002183.g003
Figure 4. Histology of mice footpads of non-treated mice or mycobacteriophage D29-treated mice. Histological sections of footpads
collected at different time points were stained with HE (A, B, D, E, H, I and J) or with ZN (C, F, G and K). For panels A, D, H and J, the scale bars
represent 100 mm. For panels B, E and I, the scale bars represent 10 mm. For panels C, F, G and K the scale bars represent 5 mm. dpi, days post-
infection. At 68 days post-infection (A–C), footpads of non-treated mice show necrotic areas (asterisks). Magnifications of panel A (rectangles) show
mononuclear cells adjacent/in necrotic areas (B). Panel C show bacteria in necrotic areas (C; arrowheads). At day 35 after treatment (day 68 post-
infection) (D–G), footpads of mycobacteriophage D29-treated mice show abundant cellular infiltration (D), composed mainly by mononuclear cells
(E). Staining for bacteria in the same tissue areas and magnifications of the bacilli (arrowheads) are shown in panels F and G. At 150 days after
treatment (H–K), footpads of mycobacteriophage D29-treated mice show a persistent inflammatory infiltrate (H–I). Staining for bacteria in remaining
necrotic areas (J) are shown in panel K.
doi:10.1371/journal.pntd.0002183.g004
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more so than antibiotic resistance [22,54]. Even though we cannot
rule out that some phage resistance can occur, the use, in this study,
of a single phage treatment dose greatly reduces this hypothesis.
To characterize the type of immune response associated with
the administration of mycobacteriophage D29 and, particularly,
how phage treatment influences the host immune response against
M. ulcerans, we carried out a comparative analysis of cytokine
kinetics in footpads and DLN, where the initiation of the adaptive
immune response occurs [38]. It is known that the differentiation/
proliferation of mycobacteria-specific lymphocytes can occur in
the DLN, early after M. ulcerans infection, and that effector T cells
are recruited to the site of infection [38], where they mediate
partial protection by enhancing IFN-c-induced macrophage
antimicrobial mechanisms. In agreement, we detected IFN-c in
the DLN, however this host response is not sufficient to inhibit the
proliferation of virulent M. ulcerans, as increasing concentrations of
mycolactone impair the effector activity of macrophages [6].
Interestingly, we observed that mycobacteriophage D29 treatment
results in a significant increase in the total number of cells in the
DLN, as well as in an increase of IFN-c levels, correlating with a
decrease in the number of viable bacteria, both in footpads and
DLN, measured at day 68 post-infection (day 35 post-treatment).
Collectively, these results suggest that the dissemination and
prolonged permanence of phages in the DLN may prevent local
M. ulcerans proliferation and the associated accumulation of
mycolactone, therefore preventing DLN destruction.
As previously described [38–40] and confirmed in this study, the
tissue destruction of the DLN was associated with bacterial
colonization, which is consistent with the spreading of M. ulcerans
from the site of infection via afferent lymphatic drainage [55,56]
On the other hand, the increased immune activation induced in
the DLN of treated mice may explain an immune-mediated
Figure 5. Histology and leukocyte kinetics in DLN of non-treated mice or mycobacteriophage D29-treated mice. Histological sections
of DLN collected at different time points were stained with HE. For panels A and B the scale bars represent 500 mm. At 68 days post-infection DLN of
non-treated mice show severe damage of the lymphoid tissue (panel A). At day 35 after treatment (day 68 post-infection), DLN structure of
mycobacteriophage D29 treated animals was maintained (panel B). Total number of cells in the DLN was determined in DLN suspensions (panel C).
Results are from one representative experiment of two independent experiments. n.d., not determined. In panel C data points represent the mean 6
SD (n = 5). Significant differences between treated and non-treated mice were performed using Student’s t test (*, p#0.05).
doi:10.1371/journal.pntd.0002183.g005
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control of bacterial proliferation in the footpad, despite the lack of
phages at the primary site of infection. In fact, as previously
described, IFN-c, and TNF play a protective role in immunity
against M. ulcerans experimental infections, contributing to control
bacterial proliferation [6,7,57]. Accordingly, we show here that
mycobacteriophage D29 treatment was associated with increased
levels of both IFN-c and TNF in M. ulcerans-infected footpads
[6,7], correlating with a predominance of a mononuclear infiltrate
and prevention of ulceration at 150 days post-infection. Addition-
ally, our histological data show that bacilli are still present in
footpad tissues, albeit with an altered morphology and poorly
stained with ZN. Although this observation may indicate that, as
described [39], M. ulcerans bacilli underwent degradation after
bacterial killing, a possible relapse of M. ulcerans infection after the
150 day period of experimental infection was not checked in this
study.
Here we show that IL-6 concentration was markedly lower in
footpads of mycobacteriophage D29 treated mice at day 68 post-
infection (day 35 after treatment) as compared to non-treated
mice, confirming that footpad tissue damage is less severe in D29
phage treated footpads.
Although production of IL-10 could be detected in skin lesions
of patients with BU [58,59] the exact role of this cytokine in the
progression of M. ulcerans infection has to be further analyzed. In
this experimental setting, it is possible that the increased levels of
IL-10 in mycobacteriophage D29 treated mice are modulating the
activity of the pro-inflammatory cytokines.
In summary, our results show that administration of the lytic
mycobacteriophage D29: (i) is an effective approach for reducing
M. ulcerans-induced pathology in the mouse model of infection; (ii)
reduced M. ulcerans numbers in the footpad and the DLN,
associated with increased IFN-c and TNF levels and; (iii) is not
associated with detectable side effects over a minimum delay of
150 day observation period.
To our knowledge, this is the first study on mycobacteriophage
therapy against M. ulcerans in vivo infection. It should be pointed out
that mice were treated at an advanced stage of M. ulcerans
infection, which is relevant for human infection since BU patients
often seek medical treatment in advanced stages of the disease.
More detailed studies examining the effects of phage dosage,
routes and timing of administration, as well as on pharmacoki-
netics, will be needed to determine if phage therapy will provide a
consistent alternative/supplement for the treatment of BU.
Although the development of a therapeutic regimen using phages
will involve a commitment to fulfill the scientific requirements of
current pharmaceutical agencies, our encouraging results justifies
further investigation on the potential of phages for the manage-
ment of this mycobacteriosis. Moreover, mycobacteriophage D29
represents an ideal agent from a regulatory standpoint in that it
has been fully characterized genetically [60] and is able to be used
on a stand-alone basis. Another approach could be based on the
therapeutic use of lysins bacteriophage proteins produced at the
end of a lytic life cycle, designed to attack peptidoglycan in order
to allow the release of the new synthesized phage particles [61].
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